מדיקינט MR כמוסות בשחרור מושהה 40 מ"ג ישראל - עברית - Ministry of Health

מדיקינט mr כמוסות בשחרור מושהה 40 מ"ג

mediline ltd. - methylphenidate hydrochloride 40 mg - modified release capsules - methylphenidate - medikinet modified release capsules are indicated as part of a comprehensive treatment program for attention-deficit/hyperactivity disorder (adhd) in children over 6 years of age when remedial measures alone prove insufficient. treatment must be under the supervision of a specialist in childhood behavioural disorders. diagnosis should be made according to dsm-iv criteria or the guidelines in icd-10.

אפידיולקס ישראל - עברית - Ministry of Health

אפידיולקס

neopharm ltd, israel - cannabidiol - תמיסה - cannabidiol 100 mg / 1 ml - cannabidiol

טקארטוס ישראל - עברית - Ministry of Health

טקארטוס

gilead sciences israel ltd - anti-cd19 car t cells - anti-cd19 car t cells

דקטרין אורל ג'ל ישראל - עברית - Ministry of Health

דקטרין אורל ג'ל

j-c health care ltd - miconazole - ג'ל - miconazole 20 mg/g - miconazole - miconazole - oral mycosis (thrush) and fungal infections of the upper gastrointestinal tract. daktarin oral gel can be used for the prevention of oral thrush in patient receiving long-term treatment with antibiotics, steroids, cytotoxic and radiation therapy.

קראון מיקרו ישראל - עברית - Ministry of Health

קראון מיקרו

perrigo israel agencies ltd - pancreatin 60.12 mg - gastro resistant pellets - multienzymes (lipase, protease etc.) - pancreatic exocrine insufficiency.

קארדוכסין פורטה ישראל - עברית - Ministry of Health

קארדוכסין פורטה

rafa laboratories ltd - dipyridamole - טבליה - dipyridamole 75 mg - dipyridamole - dipyridamole - as an adjunct to oral anticoagulants for prophylaxis of thromboembolism associated with prosthetic heart valves. reduction of proteinuria in the nephrotis syndrome. treatment of membranoproliferative glomerulonephritis. prevention of pre-eclampsia in the final trimester of pregnancy. prevention of transplant artery stenosis. prevention of post-operative thromboembolic complications of coronary artery surgery. in combination with acetylsalicylic acid in cases of recurrent deep vein thrombosis resistant to oral anticoagulants. prevention of thrombogenic manifestations. as an alternative to exercise stress in thallium myocardial imaging particularly in patients unable to exercise or in those for whom exercise may be contraindicated.

רמיפריל טבע  10 מג ישראל - עברית - Ministry of Health

רמיפריל טבע 10 מג

teva pharmaceutical industries ltd, israel - ramipril - טבליה - ramipril 10 mg - ramipril - ramipril - hypertension . congestive heart failure . reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

רמיפריל טבע  5 מג ישראל - עברית - Ministry of Health

רמיפריל טבע 5 מג

teva pharmaceutical industries ltd, israel - ramipril - טבליה - ramipril 5 mg - ramipril - ramipril - - hypertension - congestive heart failure - reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. - prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

רמיפריל טבע  5 מג ישראל - עברית - Ministry of Health

רמיפריל טבע 5 מג

teva pharmaceutical industries ltd, israel - ramipril - טבליה - ramipril 5 mg - ramipril - ramipril - - hypertension - congestive heart failure - reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. - prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

רמיפריל טבע   2.5 מג ישראל - עברית - Ministry of Health

רמיפריל טבע 2.5 מג

teva pharmaceutical industries ltd, israel - ramipril - טבליה - ramipril 2.5 mg - ramipril - ramipril - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.